1/13
07:00 am
traw
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
High
Report
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
12/23
04:14 pm
traw
Traws Pharma (NASDAQ:TRAW) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Traws Pharma (NASDAQ:TRAW) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/17
07:10 am
traw
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients [Yahoo! Finance]
High
Report
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients [Yahoo! Finance]
12/17
06:00 am
traw
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
High
Report
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
12/6
05:47 am
traw
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at Zacks Research to a "hold" rating.
Medium
Report
Traws Pharma (NASDAQ:TRAW) was upgraded by analysts at Zacks Research to a "hold" rating.
12/4
07:18 am
traw
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
Medium
Report
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $8.00 price target on the stock.
12/3
07:02 am
traw
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
Medium
Report
Traws Pharma (NASDAQ:TRAW) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
12/2
03:46 pm
traw
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
07:40 am
traw
Traws Pharma GAAP EPS of -$0.34 [Seeking Alpha]
High
Report
Traws Pharma GAAP EPS of -$0.34 [Seeking Alpha]
11/13
07:00 am
traw
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
High
Report
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
10/30
12:31 pm
traw
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Traws Pharma (NASDAQ:TRAW) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/30
12:00 pm
traw
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
Medium
Report
ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials
10/22
06:40 pm
traw
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
High
Report
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.